Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** Citalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant used primarily to treat depression and major depressive disorder. It works by increasing the amount of serotonin in the brain, which helps maintain mental balance and improve mood. Citalopram is considered one of the most selective SSRIs, with minimal effects on dopamine and norepinephrine transporters and little affinity for other receptors such as muscarinic, histaminergic, or GABAergic receptors. It does not inhibit monoamine oxidase. The drug is available as tablets, oral solution, and capsules[1][2][3][5]. Developed originally by H. Lundbeck A/S in Denmark[7], citalopram has been marketed globally under various brand names.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citalopram.